Sun Pharma Advanced Research Company share news and announcements
NSE: SPARCBSE: 532872Pharmaceuticals & BiotechnologySmall Cap
Last close ₹171.77down ₹1.32 (0.76%)BSE ₹171.75
Share price at the NSE close on 23 Oct 2026. Previous close ₹173.09.
52-week range of traded prices to 23 Oct 2026
₹108.00Low, 23 Mar 2026₹289.00High, 8 Jul 2026
- Next results date: the board meets on 2 Nov 2026 to consider: financial results.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹5,574 Cr778th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit.
- 3.5
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet.
- 4.2
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the latest balance sheet's; the one a year before is not on record.
- 118.4%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 84.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.42
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 7,97,11238.6% delivered
Sun Pharma Advanced Research Company disputes and clarifications
25 filed, newest first.
Oct 2026
4 Oct · Legal
Mar 2026
26 Mar · Legal
The exchange asked on 25 Mar 2026
Feb 2026
2 Feb · Legal
The exchange asked on 1 Feb 2026
Dec 2025
Oct 2025
29 Oct · Legal
The exchange asked on 28 Oct 2025
Jul 2025
Jun 2025
23 Jun · Legal
Exchange has sought clarification from Sun Pharma Advanced Research Company Limited for the quarter ended 31-Mar-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. The company has not submitted declaration in case of unmodified opinion(s) The response of the Company is awaited.
May 2025
30 May · Legal
The exchange asked on 28 May 2025
29 May · Legal
Mar 2025
25 Mar · Legal
The exchange asked on 25 Mar 2025
Nov 2024
26 Nov · Legal
The exchange asked on 22 Nov 2024
Jan 2024
4 Jan · Legal
The exchange asked on 3 Jan 2024
Oct 2023
19 Oct · Legal
The exchange asked on 18 Oct 2023
Apr 2023
13 Apr · Legal
The exchange asked on 12 Apr 2023
Mar 2023
24 Mar · Legal
The exchange asked on 23 Mar 2023
Sep 2022
30 Sep · Legal
The exchange asked on 29 Sep 2022
May 2021
12 May · Legal
The exchange asked on 11 May 2021
Jan 2021
1 Jan · Legal
The exchange asked on 31 Dec 2020
Sep 2019
3 Sep · Legal
Exchange has sought clarification from Sun Pharma Advanced Research Company Limited with respect to announcement dated 20-Aug-2019, regarding complaint filed by Abraxis Biosciences LLC. On basis of above the Company is required to clarify following: 1. Quantum of claims, if any 2. Expected financial implications, if any, due to compensation, penalty, etc. The response of the Company is awaited.
Oct 2015
Aug 2015
20 Aug · Legal
Clarification by Sun Pharma Advanced Research Company Limited Substantial increase in trading volumes have been observed in Sun Pharma Advanced Research Company Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Sun Pharma Advanced Research Company Limited has vide its letter inter-alia stated, "we wish to confirm that there are no material information / announcement / development (including pending / unpublished announcement) that could have triggered the jump in volume."
Jan 2015
20 Jan · Legal
Spurt in Volume : Substantial increase in trading volumes have been observed in Sun Pharma Advanced Research Company Limited.. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Sun Pharma Advanced Research Company Limited has vide its letter inter-alia stated," there is no event which will have a bearing on the performance / operations of the Company nor any price sensitive information of the Company which are reportable under clause 36 or any other clause of the listing agreement."
Jul 2014
24 Jul · Legal
Spurt in Volume : Substantial increase in trading volumes have been observed in Sun Pharma Advanced Research Company Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Sun Pharma Advanced Research Company Limited has vide its letter inter-alia stated," There is no event which will have a bearing on the performance / operations of the Company nor any price sensitivity information of the Company."
Apr 2014
30 Apr · Legal
Spurt in Volume : Substantial increase in trading volumes have been observed in Sun Pharma Advanced Research Company Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Sun Pharma Advanced Research Company Limited has vide its letter inter-alia stated,"There is no event which will have a bearing on the performance/operations of the Company nor any price sensitive information of the Company which are reportable under clause 36 or any other clause of the listing agreement with the exchanges which are not shared with the Exchanges."